Innoviva Market Cap 2012-2025 | INVA
Innoviva market cap history and chart from 2012 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of February 10, 2026 is $1.57B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.569B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $987.104B | 47.48 |
| Johnson & Johnson (JNJ) | United States | $555.945B | 21.37 |
| AbbVie (ABBV) | United States | $398.793B | 23.88 |
| Roche Holding AG (RHHBY) | Switzerland | $363.885B | 0.00 |
| Novartis AG (NVS) | Switzerland | $319.060B | 16.91 |
| Merck (MRK) | United States | $281.387B | 13.11 |
| Novo Nordisk (NVO) | Denmark | $263.122B | 15.43 |
| Pfizer (PFE) | United States | $151.581B | 8.33 |
| Sanofi (SNY) | France | $115.292B | 10.67 |